Report演題速報レポート
6月1日 演題レポート
- Colorectal Cancer
- Non-Colorectal Cancer
CSS=Clinical Science Symposia / PDS=Poster Discussion Session
Abstract #3510
FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as Initial Treatment for Metastatic Colorectal Cancer (TRIBE Study): Updated Survival Results and Final Molecular Subgroups Analyses
Fotios Loupakis, et al.
Abstract #3512
Stage III大腸癌に対する術後補助化学療法としてのS-1 vs. Capecitabineの無作為化第III相試験 (JCOG0910)
Randomized Phase III Study of Adjuvant Chemotherapy with S-1 Versus Capecitabine in Patients with Stage III Colon Cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910)
Tetsuya Hamaguchi, et al.
Abstract #3515
Stage II/III直腸癌に対する術後補助化学療法としてのS-1とUFTの無作為化比較第Ⅲ相試験 (JFMC35-C1: ACTS-RC)
A Randomized Phase III Trial Comparing S-1 Versus UFT as Adjuvant Chemotherapy for Stage II/III Rectal Cancer (JFMC35-C1: ACTS-RC)
Akihiko Murata, et al.
Abstract #3535
RAS 野生型の切除不能進行・再発大腸癌に対する1st-line治療としてのmFOLFOX6 + Panitumumab または Bevacizumabの腫瘍縮小効果
Tumor Response Outcomes in First-line Treatment of Wild-type RAS Metastatic Colorectal Carcinoma Following Modified FOLFOX6 (mFOLFOX6) + Either Panitumumab or Bevacizumab
Fernando Rivera, et al.
Abstract #3543
The PRIME Trial: Quality-adjusted Survival in Patients with RAS Wild-type Metastatic Colorectal Cancer Receiving First-line Ttherapy with Panitumumab Plus FOLFOX Versus FOLFOX Alone
Jianmin Wang, et al.
Abstract #3544
標準治療不応後の切除不能進行・再発大腸癌に対するTAS-102とBevacizumab併用療法の医師主導第I/II相臨床試験 (C-TASK FORCE)
An Investigator Initiated Multicenter Phase I/II Study of TAS-102 with Bevacizumab for Metastatic Colorectal Cancer Refractory to Standard Therapies (C-TASK FORCE)
Yasutoshi Kuboki, et al.
Abstract #3577
Stage II/III大腸癌に対するD3郭清を伴った腹腔鏡下手術 vs. 開腹手術の無作為化比較試験:JCOG0404試験の有効性に関する初回報告
A Randomized Controlled Trial to Evaluate Laparoscopic versus Open with Japanese D3 Dissection for Stage II, III Colorectal Cancer (CRC): First Efficacy Results from Japan Clinical Oncology Group Study JCOG0404
Tomonori Akagi, et al.
Abstract #3586 / #3587
Abstract #3586
ASPECCT試験の最終解析:化学療法抵抗性KRAS exon 2 野生型切除不能進行・再発大腸癌に対するPmab vs. Cmabの第III相試験 (非劣性試験)
Final Results from ASPECCT: Randomized Phase 3 Noninferiority Study of Panitumumab Versus Cetuximab in Chemorefractory Wild-type KRAS Exon 2 Metastatic Colorectal Cancer
Timothy Jay Price, et al.
Abstract #3587
化学療法抵抗性KRAS exon 2 野生型切除不能進行・再発大腸癌に対するPmab vs. Cmabの無作為化第III相試験:ASPECCT試験における低Mg血症の有無別と生存の関連の解析
Randomized Phase 3 Study of Panitumumab Versus Cetuximab in Chemorefractory Wild-type KRAS Exon 2 Metastatic Colorectal Cancer: Outcomes by Hypomagnesemia in ASPECCT
Marc Peeters, et al.
Abstract #4017
cStage IA/IB胃癌に対する腹腔鏡下手術と開腹手術によるリンパ節郭清を伴う幽門側胃切除の第III相試験 (JCOG0912):安全性解析と短期的予後成績
A Phase III Study of Laparoscopy-assisted Versus Open Distal Gastrectomy with Nodal Dissection for Clinical Stage IA/IB Gastric Cancer (JCOG0912): Analysis of the Safety and Short-term Clinical Outcomes
Masakazu Takagi, et al.
Abstract #4018
Sorafenib抵抗性進行肝細胞癌に対するS-1のプラセボ対照無作為化第III相試験 (S-CUBE)
A Randomized, Double-blind, Placebo-controlled Phase III Study of S-1 in Patients with Sorafenib-refractory Advanced Hepatocellular Carcinoma (S-CUBE)
Masatoshi Kudo, et al.
Abstract #4028
胃癌2nd-line治療としてRamucirumabを用いた2つの第III相試験、REGARDとRAINBOWのOS予後因子解析
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase 3 Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Individual Patient Data
Charles S. Fuchs, et al.
Abstract #4051
高齢者進行胃癌に対する初回治療としてのCapecitabine単独療法 vs. Capecitabine + L-OHP併用療法の無作為化比較試験: 初回中間解析の結果
First-line Capecitabine (X) Monotherapy Versus Capecitabine Plus Oxaliplatin (XELOX) in Elderly Patients with Advanced Gastric Cancer (AGC): Results from the First Interim Analysis
In Gyu Hwang, et al.
Abstract #4123
FOLFIRINOX療法に不応となった切除不能膵癌に対するnab-Paclitaxel + Gemcitabine療法:多施設共同前向き研究 (AGEO)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Adenocarcinoma after Failure of FOLFIRINOX: Results of an AGEO Multicenter Prospective Cohort
Alix Portal, et al.